<DOC>
	<DOCNO>NCT00655265</DOCNO>
	<brief_summary>This study design ass whether colesevelam give third line treatment add maximal tolerate stable dose statin ezetimibe able decrease level LDL cholesterol safe efficient manner difficult treat Familial Hypercholesterolaemia patient target level LDL cholesterol .</brief_summary>
	<brief_title>A Study Safety Efficacy Patients With Familial Hypercholesterolaemia Taking Colesevelam add-on Therapy Their Existing Medication</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type II</mesh_term>
	<mesh_term>Colesevelam Hydrochloride</mesh_term>
	<criteria>Patients must clinical diagnosis Familial Hypercholesterolaemia define EITHER a.Presence document LDLreceptor mutation OR b . History untreated LDLcholesterol level 95th percentile sex age combination documentation least one following : i.Presence typical tendon xanthoma patient first degree relative . ii . An LDLcholesterol level 95th percentile age sex first degree relative . iii . Proven coronary artery disease patient first degree relative age 60 . Patients must provide undergone lifestyle change 6 month time Screening Patients must treat least 3 consecutive month precede Screening visit lipid lower treatment regimen consist maximal tolerate combination statin ezetimibe still target LDL cholesterol 2.5 mmol/L ( 100 mg/dL ) Patients must commit follow protocol requirement evidence write informed consent Patients comfortable swallow 3 placebo tablet Patients know allergy component use colesevelam placebo medication like statin ezetimibe require participation study Patients bowel biliary obstruction Patients secondary cause hypercholesterolaemia , e.g. , dysproteinaemia , hypothyroidism , nephrotic syndrome ( define proteinuria &gt; 2 g/L ) , obstructive liver disease , pharmacological therapy , alcoholism Patients triglyceride level &gt; 3.4 mmol/L Patients dysphagia , swallow disorder , severe gastrointestinal motility disorder , inflammatory bowel disease , major gastrointestinal tract surgery Patients undergone LDLapheresis within one year prior screen visit and/or need undergo LDLapheresis Patients active liver disease unexplained persistent elevation transaminases Patients fenofibrates concomitant cholestyramine affect area curve ( AUC ) ezetimibe Patients poorlycontrolled diabetes ( i.e. , HbA1c &gt; 9 % Screening ) Patients clinically significant ( CS ) abnormal haematology , renal , laboratory parameter could result underlying malignancy systemic infection judge investigator Patients heart transplant , concurrent congestive heart failure ( NYHA Class 3 4 ) , lifethreatening ventricular arrhythmia , unstable angina , recent myocardial infarction within past 6 month prior screen , patient undergoing haemodialysis , active disease may healthy enough successfully complete protocol requirement Fertile woman pregnant , nurse use either inadequate form contraception take account recommendation adequate intake oral contraceptive outline concomitant medication section Patients recent history alcoholism drug abuse , sever emotional behavioural psychiatric problem may able adequately comply requirement study may unable consent Patients receive experimental medication participate another study use experimental drug procedure within 30 day prior sign inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>